Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping, with Becton Dickinson (BDX) and Sotera Health (SHC) looking best positioned to respond favorably to upcoming reports when considering current sentiment/positioning.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson price target lowered to $261 from $279 at Barclays
- Gregory J. Hayes Joins Becton Dickinson Board
- Becton Dickinson announces first patient treated in GalaFLEX trial
- Tariff delay positive for Mexico-exposed medtech companies, says BofA